The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are potent anti-diabetic drugs that also efficiently reduce cardiovascular deat...

Full description

Bibliographic Details
Main Authors: Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nyström, Thomas Klein, Gesine Paul, Cesare Patrone, Vladimer Darsalia
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Empagliflozin
Mouse
Sodium-glucose cotransporter 2 inhibitors
Stroke recovery
Online Access:https://doi.org/10.1186/s12933-024-02174-6

Internet

https://doi.org/10.1186/s12933-024-02174-6

Similar Items